Mind Medicine (MindMed) 대차 대조표 상태

재무 상태 기준 확인 5/6

Mind Medicine (MindMed) 의 총 주주 지분은 $262.2M 이고 총 부채는 $24.3M, 이는 부채 대 자기자본 비율을 9.3% 로 가져옵니다. 총자산과 총부채는 각각 $319.8M 및 $57.6M 입니다.

주요 정보

9.3%

부채 비율

US$24.31m

부채

이자 보상 비율	n/a
현금	US$295.28m
주식	US$262.19m
총 부채	US$57.58m
총 자산	US$319.77m

최근 재무 상태 업데이트

Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans

May 23

We're Hopeful That Mind Medicine (MindMed) (NASDAQ:MNMD) Will Use Its Cash Wisely

Feb 07

Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans

Aug 26

Recent updates

Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data

Apr 04

Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts

Feb 02

Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans

May 23

We're Hopeful That Mind Medicine (MindMed) (NASDAQ:MNMD) Will Use Its Cash Wisely

Feb 07

MindMed: Not The Horse To Back If You're Looking To Buy Psychedelics

Oct 19

MindMed announces proposed public offering of common shares

Sep 27

MindMed doses first patient in phase 1 trial examining psychedelic MDMA-like substances

Sep 20

MindMed regains compliance with Nasdaq's minimum bid price listing requirement

Sep 14

MindMed: Confusing MEME Rally Hides A Company That Looks Empty Of Value

Sep 04

Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans

Aug 26

Magic mushrooms psychedelic compound can help with treatment of alcohol use disorder

Aug 24

MindMed soars 71% as it appears to be following in Bed Bath & Beyond's footsteps

Aug 18

Mind Medicine GAAP EPS of -$0.04 beats by $0.01

Aug 11

Mind Medicine announces 1-for-15 reverse stock split

Aug 04

MindMed: Another Psychedelic Medicine Play Trading At A Potential Discount

Jul 12

재무 상태 분석

단기부채: MNMD 의 단기 자산 ( $299.4M )이 단기 부채( $33.3M ).

장기 부채: MNMD 의 단기 자산( $299.4M )이 장기 부채( $24.3M ).

부채 대 자본 내역 및 분석

부채 수준: MNMD 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: 지난 5년간 MNMD 의 부채비율이 감소했는지 판단하기에는 데이터가 부족합니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: MNMD 현재 무료 현금 흐름을 기준으로 3년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: MNMD 27.5 2.6 27.5 % 매년.

Mind Medicine (MindMed) 대차 대조표 상태

재무 상태 기준 확인 5/6

주요 정보

최근 재무 상태 업데이트

Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Mind Medicine (MindMed) (NASDAQ:MNMD) Will Use Its Cash Wisely

Mind Medicine Regains Compliance with Nasdaq's Minimum Bid Price Listing Requirement

Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans

Recent updates

Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate

CEO & Director notifies of intention to sell stock

Price target increased by 9.3% to US$26.50

Executive President exercised options and sold US$81k worth of stock

Mind Medicine (Mindmed) Inc. Presents Phase 2B Study of Mm120 for Generalized Anxiety Disorder (Gad) At American Psychiatric Association

Psychedelic Stocks: Focus On Their Cash

Mind Medicine (MindMed) Inc. has completed a Follow-on Equity Offering in the amount of $74.998573 million.

Mind Medicine (MindMed) Inc. has filed a Follow-on Equity Offering.

Mind Medicine (MindMed) Inc. to Report Q2, 2024 Results on Aug 13, 2024

Mindmed Appoints Stephanie Fagan as Chief Corporate Affairs Officer

Mind Medicine (MindMed) Inc. Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)

Mind Medicine (MindMed) Inc.(NasdaqGS:MNMD) dropped from Russell 3000E Value Index

Mind Medicine (MindMed) Inc Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors

Mind Medicine (MindMed) Inc., Annual General Meeting, Jun 10, 2024

Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data

Numinus Wellness Congratulates Mindmed on Positive Results from Phase 2B Clinical Trials of Mm120 for Generalized Anxiety Disorder

New major risk - Shareholder dilution

Mind Medicine (MindMed) Inc. has completed a Follow-on Equity Offering in the amount of $100.000002 million.

Price target increased by 10% to US$28.67

Mind Medicine (MindMed) Inc. announced that it expects to receive $75 million in funding from Deep Track Capital, LP, Commodore Capital

Mind Medicine (MindMed) Inc. has completed a Follow-on Equity Offering in the amount of $100.000002 million.

Price target increased by 7.5% to US$26.17

Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts

Mind Medicine (Mindmed) Inc. Provides Anticipated Production Milestones for 2024

Mind Medicine Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

New minor risk - Share price stability

Price target increased by 14% to US$25.83

Price target decreased by 36% to US$14.50

New major risk - Revenue and earnings growth

Price target increased by 14% to US$25.83

New minor risk - Market cap size

Mind Medicine (MindMed) Inc. Completes Enrollment of Phase 2A Trial of Mm-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)

Mind Medicine Completes Enrollment and Dosing in Study Mmed008

Chief Financial Officer recently sold US$76k worth of stock

New minor risk - Share price stability

Mind Medicine (Mindmed) Inc. Elects David Gryska to the Board of Directors

FCM MM Holdings Posts Material on Social Media Platforms

FCM MM Holdings Calls for Socially Responsible Investors to Vote for Change at Mind Medicine

FCM MM Holdings Posts Material on Twitter

FCM MM Holdings Provides Information to Shareholders of Mind Medicine

FCM MM Holdings Condemns the Report Issued by Institutional Shareholder Services

FCM MM Holdings LLC Issues a Letter to the Shareholders of Mind Medicine Inc

FCM MM Holdings Posts Materials to Reddit

FCM MM Holdings Sends Letter to Shareholders of Mind Medicine (MindMed)

Mind Medicine Posts Materials to Twitter

FCM MM Holdings Issues an Investor Presentation to Shareholders of Mind Medicine

Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans

Mind Medicine (MindMed) Inc. Enters into Phase 2b Clinical Trial Evaluating MM-120 (lysergide D-Tartrate) for GAD

FCM Director Nominees Will Put MindMed Drug Development Process Back on Track

Mind Medicine Launches a Website and Post the Materials

Mind Medicine (MindMed) Inc., Annual General Meeting, Jun 15, 2023

We're Hopeful That Mind Medicine (MindMed) (NASDAQ:MNMD) Will Use Its Cash Wisely

Price target decreased by 11% to US$27.63

High number of new and inexperienced directors

FCM MM Holdings LLC Sends a Letter to Mind Medicine (MindMed) Inc

FCM MM HOLDINGS, LLC Demands Federal Investigation to Probe Serious Allegations of Misconduct at Mind Medicine (MindMed) Inc

MindMed: Not The Horse To Back If You're Looking To Buy Psychedelics

Mind Medicine Announces Initiation of Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA

FCM MM HOLDINGS Sends Letter to the Board of Mind Medicine

MindMed announces proposed public offering of common shares

Mind Medicine (MindMed) Inc. Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances

Price target decreased to US$51.10

MindMed doses first patient in phase 1 trial examining psychedelic MDMA-like substances

Mind Medicine Regains Compliance with Nasdaq's Minimum Bid Price Listing Requirement

MindMed regains compliance with Nasdaq's minimum bid price listing requirement

Mind Medicine (MindMed) Inc. Announces Positive Results from Collaborators' Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal

MindMed: Confusing MEME Rally Hides A Company That Looks Empty Of Value

Mind Medicine (MindMed) Inc. Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans

Magic mushrooms psychedelic compound can help with treatment of alcohol use disorder